封面
市場調查報告書
商品編碼
1251434

血友病治療市場:按產品類型、分銷渠道、地區 - 規模、份額、展望、機會分析,2023-2030 年

Hemophilia Treatment Market, By Product Type, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

血友病是一種遺傳性出血性疾病,其中稱為凝血因子的蛋白質缺乏或水平低,例如凝血因子 VIII。 大約有 13 種凝血因子,它們與血小板一起作用以凝結血液。 血友病分為 A、B 和 C 三種類型,其中 A 型血友病最常見,由凝血因子 VIII 缺乏引起。 血友病 B 是由因子 IX 缺乏引起的,血友病 C 是由因子 XI 缺乏引起的。 在大多數情況下,血友病是通過家庭成員遺傳的。 它主要遺傳給男孩。 血友病的主要治療方法是靜脈內補充血液中的凝血因子。 然而,血友病治療的高成本、藥物短缺以及與血漿衍生產品相關的嚴重不良事件預計會阻礙市場增長。 因此,預計血友病的發病率和患病率將上升,從而推動預測期內市場的增長。 這導致各大公司推出產品以滿足消費者未被滿足的需求。 有關產品發布和治療的有利監管情景和指南也有望在預測期內推動市場增長。

市場動態

政府加大對血友病治療的投入,預計將在預測期內推動血友病治療市場的增長。 例如,根據 2021 年 6 月在國家醫學圖書館發表的一篇文章,世界血友病聯合會 (WFH) 開始通過人道主義援助計劃在低收入和中等收入國家分發凝血因子濃縮物和 emicizumab。 該計劃旨在改善發展中國家數量有限的 PWH 的生活。

這項研究的主要特點

  • 本報告對全球血友病藥物市場進行了深入分析,包括以 2022 年為基準年的預測期(2023-2030 年)的市場規模(美國)和復合年增長率 (CAGR)。已發布.
  • 它闡明了各個細分市場的潛在收入機會,並概述了該市場具有吸引力的投資建議矩陣。
  • 它還提供有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
  • 本文根據以下參數介紹了全球血友病治療市場的主要參與者:公司概況、產品組合、主要亮點、財務業績和戰略。
  • 本研究涵蓋的主要公司包括武田製藥有限公司、賽諾菲 S.A.、Octapharma AG、瑞典孤兒 Biovitrum AB、百特國際公司、百健公司、拜耳公司、CSL Behring、Ferring B.V.、輝瑞, Inc.、Kedrion、Novo Nordisk A/S 和 F. Hoffmann-La Roche AG。
  • 從這份報告中獲得的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。.
  • 血友病治療全球市場報告面向該行業的各種利益相關者,包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以通過用於分析全球血友病治療市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

  • 調查目的
  • 先決條件
  • 縮寫說明

第二章市場範圍

  • 報告內容
    • 市場定義和範圍
  • 執行摘要
    • 按產品類型劃分的市場概況
    • 市場概況:按分銷渠道
    • 市場概況:按地區
  • 連貫機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

  • 市場動態
    • 司機
    • 約束因素
    • 市場機會
  • 影響分析
  • 最近的產品發布狀態
  • 流行病學
  • 合併/收購/合作
  • 監管場景
  • 主要發展
  • 害蟲分析

第 4 章全球血友病藥物市場 - 冠狀病毒 (COVID-19) 大流行的影響

  • 經濟影響
  • COVID-19 流行病學
  • 對供需的影響

第 5 章全球血友病藥物市場(按產品類型):2017-2030

  • 重組凝血因子
  • 血漿衍生凝血因子
  • 抗纖維蛋白溶解藥
  • 去氨加壓素

第 6 章全球血友病藥物市場(按分銷渠道):2017-2030

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 7 章。全球血友病藥物市場:地區,2017-2030

  • 北美
  • 美國
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地區
  • 歐洲
  • 英國
  • 德國
  • 意大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 東盟
  • 澳大利亞
  • 韓國
  • 其他亞太地區
  • 中東
  • 海灣合作委員會
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中非
  • 南非

第八章競爭格局

  • Takeda Pharmaceutical Co., Ltd.
  • Sanofi S.A.
  • Octapharma AG
  • Swedish Orphan Biovitrum AB
  • Baxter International Inc.
  • Biogen Inc.
  • Bayer AG
  • CSL Behring
  • Ferring B.V.
  • Pfizer, Inc.
  • Kedrion
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche AG

第 9 章

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI2012

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor such as factor VIII. There are around 13 types of clotting factors that work with blood platelets to help in clotting of blood. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency of factor VIII. Hemophilia B occurs due to deficiency of factor IX, and Hemophilia C is caused due to factor XI deficiency.In most cases, hemophilia is passed down through families that are inherited. It is mostly passed to the male childrens. The primary treatment for hemophilia is to replace the clotting factor in the blood though intravenous infusions. However, high cost of hemophilia treatment, lack of medicines and serious adverse events associated with plasma derived derived products is expected to hinder the market growth. Consequently, rising incidence and prevalence of hemophilic disorders are expected to boost growth of the market over the forecast period. This has led to product launches by key players to fulfill the unmet needs of consumers. Favorable regulatory scenarios and guidelines for the product launches and treatment are other factors that are expected to propel growth of the market over the forecast period.

Market Dynamics

Increasing government initiatives towards hemophilia treatment is likely expected to propel the growth of hemophilia treatment market over the forecast period. For instance, according to the article published in National Library of Medicine in June 2021, World Federation of Hemophilia(WFH) started distribution of coagulation factor concentrates and emicizumab in low- and low-middle-income countries through a humanitarian aid program. This programwill hwlp to improve life of a limited number of PWH in the developing world.

Key features of the study:

  • This report provides an in-depth analysis of the global hemophilia treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hemophilia treatment market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, and F. Hoffmann-La Roche AG
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemophilia treatment market

Detailed Segmentation:

  • Global Hemophilia Treatment Market, By Product Type:
    • Plasma Derived Coagulation Factor
    • Recombinant Coagulation Factor
    • Antifibrinolytic Agents
    • Desmopressin
  • Global Hemophilia Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hemophilia Treatment Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Takeda Pharmaceutical Co., Ltd*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Sanofi S.A.
    • Octapharma AG
    • Swedish Orphan Biovitrum AB
    • Baxter International Inc.
    • Biogen Inc
    • Bayer AG
    • CSL Behring
    • Ferring B.V.
    • Pfizer, Inc.
    • Kedrion
    • Novo Nordisk A/S
    • F. Hoffmann-La Roche AG

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product Type
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Product Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Hemophilia Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Hemophilia Treatment Market, By Product Type, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017- 2030
    • Segment Trends
  • Recombinant Coagulation Factor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Plasma Derived Coagulation Factor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Antifibrinolytic Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Desmopressin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

6. Global Hemophilia Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

7. Global Hemophilia Treatment Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

8. Competitive Landscape

  • Takeda Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Octapharma AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Swedish Orphan Biovitrum AB
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Baxter International Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Biogen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • CSL Behring
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ferring B.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Kedrion
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novo Nordisk A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • F. Hoffmann-La Roche AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

9. Section

  • Research Methodology
  • About Us